COEPTIS, Inc

“COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing” https://lnkd.in/e_sM_UHB #OpenAi $COEP #COEPVentures #AiNews #Blockchain #Token #Coeptis #Ai #Technology #Aitechnology #MLM #NextGenAl #Biotechnology #celltherapy #cryptonews #NexGenAiAffiliatesNetwork

“COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups” COEP announces another milestone in joining the $700B+ global Ai Market https://lnkd.in/gRwuxJHq #OpenAi #COEPVentures #AiNews #Blockchain #Token #Coeptis #Ai #Technology #Aitechnology #MLM #NextGenAl #Biotechnology #celltherapy #cryptonews #NexGenAiAffiliatesNetwork

Phase 1 Data on DVX201: study results demonstrate the safety and feasibility of adoptive immunotherapy using allogeneic off-the-shelf NK cells in hospitalized patients with COVID at high risk for progression of disease. DVX201 is the first allogeneic #NKcell therapy derived from pooled donor cord blood CD34+ cells that was administered to 9 patients with no dose limiting toxicities, cytokine release syndrome or infusion toxicities. ICYMI, read more: https://bit.ly/4hGGCnS #ClinicalTrial #Research #Biotech

Coeptis is developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with leading medical researchers. Discover the science behind our CAR therapy in development: https://lnkd.in/dg4DafCz #Biotech #Biotechnology

Coeptis recently announced the official launch of Coeptis Technologies, a new division aimed at diversifying and enhancing the company's growth potential. CEO Dave Mehalick commented, "We are embarking on an exciting journey of expansion that will not only enhance our presence in the biopharmaceutical sector but also venture into the high-growth technology sector. By establishing Coeptis Technologies, we are strategically positioning ourselves to leverage the unique opportunities present in these two dynamic industries. Our commitment to deliver unprecedented value to our shareholders is stronger than ever as we pursue innovative solutions that address the evolving needs of the market." In case you missed the announcement, dive into the press release here: https://bit.ly/4gO5w3D #Tech #AI #Biotech #Science

Reflecting on a year of developments and collaboration, Coeptis Therapeutics wishes our dedicated team, partners, and stakeholders a joyous holiday season and a prosperous New Year. We are grateful of your support in advancing our mission to develop innovative cell therapies. #HappyHolidays

Joshua Hill, MD, associate professor and physician at Fred Hutch Cancer Center and corresponding author of the Phase 1 study evaluating DVX201, an allogeneic natural killer (NK) cell therapy, for the treatment of patients hospitalized with COVID-19 comments: "Despite advances in treatment and prevention strategies for SARS-CoV-2, COVID-19 still results in substantial morbidity in certain patient populations underscoring the ongoing need for additional therapeutic options, particularly among immune compromised individuals. Although the study was not designed to assess efficacy, our findings demonstrate the safety and potential utility of NK cell therapy as a complementary therapeutic strategy for viral infections in high-risk patients." To access the full publication in Molecular Therapy Methods and Clinical Development, please visit: https://bit.ly/4i6P8N2 #Biotech #Science #COVID #Research

Phase 1 Data on DVX201 for COVID-19: Results from the clinical trial demonstrated the safety and feasibility of DVX201 as a potential treatment for patients with active SARS-CoV-2 infections. The following key findings are highlighted: ? First Demonstration of Safety: This is the first known study to demonstrate the safety of adoptive immunotherapy with allogeneic, off-the-shelf NK cells in patients with active COVID-19, especially those at high risk for disease progression. ? Innovative NK Cell Therapy: DVX201 is the first allogeneic NK cell adoptive immunotherapy used clinically that is derived from pooled donor cord blood CD34+ cells, offering a scalable, consistent, and cost-effective solution to barriers in the allogeneic cell therapy space. ? No Adverse Events: DVX201 infusions were safe and well-tolerated, with no treatment-related adverse events, including no cytokine release syndrome (CRS). In case you missed the news, read the press release here: https://bit.ly/4hGGCnS #CellTherapy #COVID #Biotech

Coeptis Therapeutics is expanding its capabilities through the intended acquisition of NexGenAI Affiliates Network. This move will allow us to leverage AI and RPA to optimize marketing campaigns, streamline workflows, and generate actionable insights, ultimately driving growth and value in the biotech, pharmaceutical, and MLM industries. CEO Dave Mehalick comments, “In industries like biotech, pharma, and MLM, where competition is so high and regulatory challenges are complex, having advanced tools to optimize marketing, streamline operations, and drive measurable results is critical." Read the full press release: https://bit.ly/3OCRGVC #AI #BusinessGrowth #Innovation #Pharmaceuticals #Biotech

Coeptis Therapeutics CEO, Dave Mehalick, on the Future of Cell Therapy with Snap-Car. “Our vision for SNAP-CAR goes beyond the current cell therapy landscape, our approach is two-fold. We’re combining innovative cell engineering technology with an established, allogeneic cell generation platform to enable a truly universal CAR-therapy. The value proposition for the cell therapy market isn’t based on where the market sits today. Rather it centers on its transformative potential to address unmet medical needs, improve patient outcomes, and ultimately reshape the future of healthcare.” https://coeptistx.com/ #CellTherapy #Biotech #Innovation #SNAPCAR #NKCells